You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Research & Development
Eurofins Launches New Tests and Massive Capacity for Detecting and Monitoring New Variants of SARS-CoV-2
15 January 2021 - - Luxembourg-based testing and laboratory services group Eurofins (PAR: ERF) has launched initiatives to support health authorities' variant detection and monitoring programmes, the company said.
These include increasing, to more than 5,000 full genomes per day, the capacity for its ARTIC Next Generation Sequencing.
Eurofins has launched NovaType, a SARS-CoV-2 RT-PCR assay, clinically validated for the identification of B.1.1.7 and B.1.351 variants with a short turn-around time, ideal for retesting millions of positive samples to detect if the virus is the B.1.1.7 or B.1.351 variant.
NovaType is already available as a Laboratory Developed Test in Germany and will shortly be made available to the more than 50 Eurofins laboratories worldwide testing patients for COVID-19.
NovaType is being made available to health authorities in a number of European countries for trial and potential inclusion in their monitoring programmes in response to these new variants.
The NovaType assay will also be launched as a Research Use Only kit in Europe by the end of January 2021.
As previously outlined, the Eurofins-Viracor SARS-CoV-2 RT-PCR diagnostic test, has been ranked as the most sensitive out of more than 115 kits evaluated by the FDA SARS-CoV-2 Reference Panel.
Furthermore, this RT-PCR test maintains very high sensitivity in the detection of variants such as B.1.1.7 and B.1.351.
Through Eurofins' current COVID-19 testing and clinical diagnostics activities globally and its partnerships with leading pharmaceutical and vaccine companies, the group is able to closely monitor the identification of new variants of SARS-CoV-2 and intends to add new detection capabilities to NovaType as additional variants appear.
Eurofins said its ability to produce and distribute primers and probes, and commercial PCR kits, additionally benefits the speed of development of new assays.
With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins' companies offer a portfolio of over 200,000 analytical methods.
These include increasing, to more than 5,000 full genomes per day, the capacity for its ARTIC Next Generation Sequencing.
Eurofins has launched NovaType, a SARS-CoV-2 RT-PCR assay, clinically validated for the identification of B.1.1.7 and B.1.351 variants with a short turn-around time, ideal for retesting millions of positive samples to detect if the virus is the B.1.1.7 or B.1.351 variant.
NovaType is already available as a Laboratory Developed Test in Germany and will shortly be made available to the more than 50 Eurofins laboratories worldwide testing patients for COVID-19.
NovaType is being made available to health authorities in a number of European countries for trial and potential inclusion in their monitoring programmes in response to these new variants.
The NovaType assay will also be launched as a Research Use Only kit in Europe by the end of January 2021.
As previously outlined, the Eurofins-Viracor SARS-CoV-2 RT-PCR diagnostic test, has been ranked as the most sensitive out of more than 115 kits evaluated by the FDA SARS-CoV-2 Reference Panel.
Furthermore, this RT-PCR test maintains very high sensitivity in the detection of variants such as B.1.1.7 and B.1.351.
Through Eurofins' current COVID-19 testing and clinical diagnostics activities globally and its partnerships with leading pharmaceutical and vaccine companies, the group is able to closely monitor the identification of new variants of SARS-CoV-2 and intends to add new detection capabilities to NovaType as additional variants appear.
Eurofins said its ability to produce and distribute primers and probes, and commercial PCR kits, additionally benefits the speed of development of new assays.
With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins' companies offer a portfolio of over 200,000 analytical methods.
Login
Related Headlines
Seqirus's FLUCELVAX QUADRIVALENT granted US FDA Expanded Age Indication
Abbott's Alinity m Resp-4-Plex molecular assay granted US FDA Emergency Use Authorisation
US FDA Approves Proxalutamide Phase III Clinical Trial for the Treatment of COVID-19 Patients